Key Takeaways
- Genmab has transitioned from primarily out-licensing its antibody candidates to co-developing and co-commercializing them, and now aims to bring forward wholly owned assets on its own.
- The acquisition of ProfoundBio gave Genmab new ADC capabilities and the ADC Rina-S, one of two wholly owned programs now in Phase III studies.
- The company continues to pursue deals to expand its late-stage pipeline and commercial portfolio before its largest source of revenue – royalties from J&J’s Darzalex – goes away in 2030.
Developing antibody therapeutics, out-licensing the drugs to larger companies and collecting royalty revenue from the resulting commercial products has been a lucrative business for Genmab
In Vivo sister publication Scrip spoke with Genmab chief medical officer Tahamtan Ahmadi at the J.P. Morgan Healthcare Conference in January about key milestones in the company’s growth and how it plans to build on those efforts this year